Relapses and treatment status in elderly and non-elderly patients with eosinophilic granulomatosis with polyangiitis: A retrospective observational study using Japanese nationwide claims data
Modern Rheumatology · 2025
DOI: 10.1093/mr/roaf026 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Masami Taniguchi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Kanagawa, Japan. Hauptthemen laut MEDLINE: Immunosuppressive Agents, Granulomatosis with Polyangiitis, Biological Products, Churg-Strauss Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
This study aimed to better understand the relapse rate for eosinophilic granulomatosis with polyangiitis, a rare, debilitating form of vasculitis, in Japanese elderly and non-elderly patients, along with their treatment statuses.
Methods
This retrospective, observational study used claims data from April 2019 to March 2022 representing approximately 8 million insured individuals in Japan. Patients aged ≥18 years were identified and stratified into elderly (≥65 years) and non-elderly (<65 years) groups. The proportion of patients experiencing relapses and their treatment statuses were assessed during a 1-year follow-up period.
Results
Among the 651 eligible patients with eosinophilic granulomatosis with polyangiitis enrolled, 38.86% experienced a relapse during the follow-up period. This proportion was similar between the elderly (36.34%) and non-elderly (42.59%) groups. Moreover, fewer elderly than non-elderly patients were prescribed biologics (22.16% vs. 37.26%) and immunosuppressants (20.36% vs. 29.28%), despite having higher percentages of corticosteroid-related comorbidities.
Conclusions
The disease burden of eosinophilic granulomatosis with polyangiitis in Japan remains substantial, with over one-third of patients experiencing a relapse, regardless of age. Age-specific management strategies optimizing biologics and immunosuppressant use while minimizing adverse events are needed to improve the outcomes of these patients in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Kanagawa, Japan.
- Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
- Medical Affairs, AstraZeneca K.K., Osaka, Japan.
- Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan.
ORCID-Profile: Masami Taniguchi
Zitieren
APA
Taniguchi, M., Koike, H., Oka, H., Ono, K., Sumi, K., Kato, Y., Arita, Y., Fujiwara, M., Makita, N., & Amano, K. (2025). Relapses and treatment status in elderly and non-elderly patients with eosinophilic granulomatosis with polyangiitis: A retrospective observational study using Japanese nationwide claims data. Modern Rheumatology. https://doi.org/10.1093/mr/roaf026
Vancouver
Taniguchi M, Koike H, Oka H, Ono K, Sumi K, Kato Y, et al. Relapses and treatment status in elderly and non-elderly patients with eosinophilic granulomatosis with polyangiitis: A retrospective observational study using Japanese nationwide claims data. Modern Rheumatology. 2025. doi:10.1093/mr/roaf026
BibTeX
@article{Taniguchi2025,
author = {Taniguchi, Masami and Koike, Haruki and Oka, Hayato and Ono, Keita and Sumi, Kazuya and Kato, Yuki and Arita, Yoshifumi and Fujiwara, Masakazu and Makita, Naoyuki and Amano, Koichi},
title = {Relapses and treatment status in elderly and non-elderly patients with eosinophilic granulomatosis with polyangiitis: A retrospective observational study using Japanese nationwide claims data},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roaf026}
}
EUVIMED